A phase 1 randomized, placebo-controlled, single ascending dose study to examine the safety, tolerability, and pharmacokinetics of CNP8 in healthy adults

This $2,199,979 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding a Phase 1 randomized, placebo-controlled, single ascending dose study to examine the safety, tolerability, and pharmacokinetics of the compound CNP8 in healthy adults. The award recipient, Neomatrix Therapeutics Inc., is a self-certified small disadvantaged business providing biomedical research and advanced wound treatment products and services. This 3-year grant, awarded on Sep 30, 2023, will be used to conduct the clinical trial in Stony Brook, NY to support defense health programs and investigate medical solutions for the battlefield. Neomatrix Therapeutics Inc. has also received previous federal grant and contract awards from the Defense Health Agency to develop CNP8 delivered in a tyrosine-derived fiber mat for reducing burn injury progression, speeding wound closure, and mitigating scarring.